Insider buy: ProMIS Neurosciences (PMN) CDO acquires 1,629 shares at $15.35
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
ProMIS Neurosciences Inc. Chief Development Officer Johanne Kaplan bought 1,629 common shares in an open-market purchase at $15.35 per share. After this transaction, Kaplan directly owns 3,941 common shares, modestly increasing personal equity exposure to the company.
Positive
- None.
Negative
- None.
Insider Trade Summary
Net Buyer: 1,629 shares ($25,005)
Net Buy
1 txn
Insider
Kaplan Johanne
Role
Chief Development Officer
Bought
1,629 shs ($25K)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Purchase | Common Shares | 1,629 | $15.35 | $25K |
Holdings After Transaction:
Common Shares — 3,941 shares (Direct)
Footnotes (1)
FAQ
What insider transaction did ProMIS Neurosciences (PMN) report on this Form 4?
ProMIS Neurosciences reported that Chief Development Officer Johanne Kaplan purchased 1,629 common shares. The transaction was an open-market purchase at a price of $15.35 per share, increasing Kaplan’s directly held stake in the company.
What role does Johanne Kaplan hold at ProMIS Neurosciences (PMN)?
Johanne Kaplan serves as Chief Development Officer at ProMIS Neurosciences. The Form 4 identifies her as an officer of the company and reports her personal open-market purchase of 1,629 common shares at $15.35 per share.
Was the ProMIS Neurosciences (PMN) insider transaction a buy or a sell?
The transaction was a buy. The Form 4 classifies it as an open-market purchase of 1,629 common shares, with transaction code “P” and direction noted as a net buy, increasing Johanne Kaplan’s directly owned share position.
Is Johanne Kaplan’s ownership in ProMIS Neurosciences (PMN) direct or indirect?
Kaplan’s reported holdings are direct. The Form 4 lists the ownership code as “D” for direct, indicating the 3,941 common shares, including the newly purchased 1,629 shares, are held in her own name rather than through another entity.